Revenue Update on Synthetic Biologics Inc(NYSEMKT:SYN)

Synthetic Biologics Inc(NYSEMKT:SYN) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Earnings per share were $-0.10. Analysts had estimated an EPS of $-0.12.

Synthetic Biologics Inc (SYN) made into the market gainers list on Fridays trading session with the shares advancing 0.58% or 0.01 points. Due to strong positive momentum, the stock ended at $1.72, which is also near the day’s high of $1.72. The stock began the session at $1.68 and the volume stood at 3,03,415 shares. The 52-week high of the shares is $3.44 and the 52 week low is $0.93. The company has a current market capitalization of $157 M and it has 9,12,69,586 shares in outstanding.

Synthetic Biologics Inc. is a clinical-stage biotechnology company. The Company is developing pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C) and a monoclonal antibody combination for the treatment of Pertussis. In addition the Company is developing a Phase II oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *